Beijing China Sciences Runyu Co., Ltd. is a specialized company engaged in the research, development, manufacturing, and distribution of advanced medical equipment and devices. Primarily, its operations are centered on producing cutting-edge diagnostic apparatus that enhances efficiency and precision in the medical field. The company's products are integral to various healthcare sectors, including hospitals, clinics, and research institutions, where high-quality diagnostic tools are crucial for patient care and research activities. Beijing China Sciences Runyu Co., Ltd. plays a significant role in the healthcare infrastructure by providing reliable and innovative equipment that supports the medical community's efforts to improve patient outcomes. Based in Beijing, the company leverages its location in one of China's major hubs for technological and scientific advancement to collaborate with leading medical researchers and practitioners in developing its product offerings. As healthcare technology continues to evolve, Beijing China Sciences Runyu Co., Ltd. remains a key participant in the market, contributing to advancements in medical diagnostics both domestically and internationally.
Industry
Waste Management
Industrials sector · China
Coordination
Placeholder CorpCoordination
Example HoldingsCoordination
Sample IncCoordination
Stories
Structural patterns identified in Beijing China Sciences Runyu Co., Ltd.
No stories identified yet.
Key Metrics
Market Capitalization
10.20BCNY
NormalMar 18, 2026
Trailing P/E
28.88CNY
NormalMar 18, 2026
Revenue (TTM)
1.87BCNY
NormalMar 18, 2026
Forward Yield
1.73%
Annual Rate
CNY 0.12
Paid semi-annual
Payout Ratio
55.4%
Sustainable
Loading dividend history...
Track Record
Frequency
Semi-Annual
Payback Period
31.5 yr
Years to recoup investment via dividends alone
Upcoming
Ex-Dividend Date
Nov 4, 2025
Valuation8
Market Capitalization
10.20BCNY
NormalMar 18, 2026
Enterprise Value
12.35BCNY
NormalMar 18, 2026
Trailing P/E
28.88CNY
Similar Stocks
No similar stocks identified yet.
Related Articles
No related articles yet.
Profit Margin
20.39%
Normal
Mar 18, 2026
Beta
0.4970CNY
NormalMar 18, 2026
52-Week Change
19.48CNY
ExtremeMar 18, 2026
Forward Annual Dividend Yield
1.73%
NormalMar 18, 2026
Normal
Mar 18, 2026
Forward P/E
18.26CNY
NormalMar 18, 2026
Price to Sales (TTM)
5.45CNY
NormalMar 18, 2026
Price to Book (MRQ)
2.82CNY
NormalMar 18, 2026
Enterprise to Revenue
6.59CNY
NormalMar 18, 2026
Enterprise to EBITDA
17.68CNY
NormalMar 18, 2026
Profitability & Growth58
Gross Margin
48.22%
NormalMar 18, 2026
Profit Margin
20.39%
NormalMar 18, 2026
Operating Margin
7.52%
NormalMar 18, 2026
Return on Assets (TTM)
0.0428CNY
NormalMar 18, 2026
Return on Equity (TTM)
0.0969CNY
NormalMar 18, 2026
Revenue (TTM)
1.87BCNY
NormalMar 18, 2026
Revenue per Share (TTM)
1.27CNY
NormalMar 18, 2026
Quarterly Revenue Growth
0.2960CNY
NormalMar 18, 2026
Gross Profit (TTM)
463.26MCNY
NormalMar 18, 2026
EBITDA
532.31MCNY
ExtremeMar 18, 2026
Net Income (TTM)
381.76MCNY
NormalMar 18, 2026
Quarterly Earnings Growth (YoY)
0.4600CNY
NormalMar 18, 2026
Operating Cash Flow (TTM)
389.68MCNY
NormalMar 18, 2026
Levered Free Cash Flow (TTM)
320.69MCNY
NormalMar 18, 2026
Forward Annual Dividend Rate
0.1200CNY
NormalMar 18, 2026
Forward Annual Dividend Yield
1.73%
NormalMar 18, 2026
Trailing Annual Dividend Rate
0.1950CNY
NormalMar 18, 2026
Trailing Annual Dividend Yield
2.81%
NormalMar 18, 2026
Payout Ratio
0.5540CNY
NormalMar 18, 2026
Minority Interest (Equity)
331.82M
NormalFY2024 · Dec 31, 2024
Revenue
1.66B
NormalFY2024 · Dec 31, 2024
Cost of Goods Sold
996.33M
NormalFY2024 · Dec 31, 2024
Gross Profit
666.47M
NormalFY2024 · Dec 31, 2024
Operating Income
480.02M
NormalFY2024 · Dec 31, 2024
Pre-tax Income
401.32M
NormalFY2024 · Dec 31, 2024
Income Tax Expense
39.68M
NormalFY2024 · Dec 31, 2024
Net Income
361.64M
NormalFY2024 · Dec 31, 2024
EBIT
484.73M
NormalFY2024 · Dec 31, 2024
ebitda-income
736.44M
NormalFY2024 · Dec 31, 2024
Research & Development
48.76M
NormalFY2024 · Dec 31, 2024
Selling, General & Administrative
46.53M
NormalFY2024 · Dec 31, 2024
Other Operating Expenses
16.25M
NormalFY2024 · Dec 31, 2024
Non-operating Interest Income
19.65M
NormalFY2024 · Dec 31, 2024
Non-operating Interest Expense
83.41M
NormalFY2024 · Dec 31, 2024
EPS (Basic)
0.2200
NormalFY2024 · Dec 31, 2024
EPS (Diluted)
0.2200
NormalFY2024 · Dec 31, 2024
Basic Shares Outstanding
1.46BShares
NormalFY2024 · Dec 31, 2024
Diluted Shares Outstanding
1.46BShares
NormalFY2024 · Dec 31, 2024
Net Income from Continuing Operations
361.64M
NormalFY2024 · Dec 31, 2024
Minority Interests (P&L)
-40.94M
NormalFY2024 · Dec 31, 2024
Preferred Stock Dividends
0.00
NormalFY2024 · Dec 31, 2024
Operating Cash Flow
389.68M
NormalFY2024 · Dec 31, 2024
Free Cash Flow
166.40M
NormalFY2024 · Dec 31, 2024
Cash & Cash Equivalents (End of Period)
993.09M
NormalFY2024 · Dec 31, 2024
Net Income (CF Statement)
361.64M
NormalFY2024 · Dec 31, 2024
Other Non-cash Items
94.51M
NormalFY2024 · Dec 31, 2024
Change in Accounts Receivable (CF)
-108.03M
NormalFY2024 · Dec 31, 2024
Change in Other Assets/Liabilities
41.56M
NormalFY2024 · Dec 31, 2024
Capital Expenditures
-514.75M
NormalFY2024 · Dec 31, 2024
Net Acquisitions
-14.61M
NormalFY2024 · Dec 31, 2024
Purchase of Investments
-10.00K
NormalFY2024 · Dec 31, 2024
Other Investing Activity
-11.00M
NormalFY2024 · Dec 31, 2024
Net Investing Cash Flow
-540.37M
NormalFY2024 · Dec 31, 2024
Long-term Debt Issuance
1.05B
NormalFY2024 · Dec 31, 2024
Long-term Debt Payments
-831.81M
NormalFY2024 · Dec 31, 2024
Common Dividends Paid
-221.48M
NormalFY2024 · Dec 31, 2024
Other Financing Charges
-114.16M
NormalFY2024 · Dec 31, 2024
Net Financing Cash Flow
-122.23M
NormalFY2024 · Dec 31, 2024
Financial Strength29
Shares Outstanding
1.47BShares
NormalMar 18, 2026
Float Shares
610.96MCNY
NormalMar 18, 2026
% Held by Insiders
0.5901CNY
NormalMar 18, 2026
% Held by Institutions
0.0290CNY
NormalMar 18, 2026
Total Cash (MRQ)
956.11MCNY
NormalMar 18, 2026
Total Cash per Share (MRQ)
0.6500CNY
NormalMar 18, 2026
Total Debt (MRQ)
2.88BCNY
NormalMar 18, 2026
Total Debt to Equity (MRQ)
72.50CNY
ExtremeMar 18, 2026
Current Ratio (MRQ)
1.58CNY
NormalMar 18, 2026
Book Value per Share (MRQ)
2.46CNY
NormalMar 18, 2026
Total Assets
7.49B
NormalFY2024 · Dec 31, 2024
Total Current Assets
1.99B
NormalFY2024 · Dec 31, 2024
Total Liabilities
3.58B
NormalFY2024 · Dec 31, 2024
Total Non-current Assets
5.50B
NormalFY2024 · Dec 31, 2024
Total Non-current Liabilities
2.45B
NormalFY2024 · Dec 31, 2024
Total Current Liabilities
1.13B
NormalFY2024 · Dec 31, 2024
Cash
993.09M
NormalFY2024 · Dec 31, 2024
Cash Equivalents
30.21M
NormalFY2024 · Dec 31, 2024
Cash & Cash Equivalents
1.02B
NormalFY2024 · Dec 31, 2024
Accounts Receivable
642.56M
NormalFY2024 · Dec 31, 2024
Inventory
89.84M
NormalFY2024 · Dec 31, 2024
Accounts Payable
530.32M
NormalFY2024 · Dec 31, 2024
Short-term Debt
304.98M
NormalFY2024 · Dec 31, 2024
Other Current Liabilities
10.16M
NormalFY2024 · Dec 31, 2024
Long-term Debt
2.07B
NormalFY2024 · Dec 31, 2024
Other Non-current Liabilities
156.60M
NormalFY2024 · Dec 31, 2024
Common Stock (Book)
1.47B
NormalFY2024 · Dec 31, 2024
Retained Earnings
907.38M
NormalFY2024 · Dec 31, 2024
Total Shareholders' Equity
3.91B
NormalFY2024 · Dec 31, 2024
Market & Technical9
52-Week Low
4.95CNY
NormalMar 18, 2026
52-Week High
8.04CNY
NormalMar 18, 2026
52-Week Change
19.48CNY
ExtremeMar 18, 2026
Beta
0.4970CNY
NormalMar 18, 2026
50-Day MA
6.45CNY
NormalMar 18, 2026
200-Day MA
5.70CNY
NormalMar 18, 2026
Avg 10-Day Volume
72.93MCNY
NormalMar 18, 2026
Avg 30-Day Volume
60.89MCNY
NormalMar 18, 2026
Diluted EPS (TTM)
0.2400CNY
NormalMar 18, 2026
Screen for dividend patterns
Find other stocks with similar dividend characteristics in the screener.